Key terms
About TTNP
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TTNP news
Apr 03
5:23pm ET
Titan Pharmaceuticals Overhauls Leadership, Settles with Ex-Directors
Feb 08
9:40am ET
Titan Pharmaceuticals trading resumes
Feb 08
9:30am ET
Titan Pharmaceuticals trading halted, volatility trading pause
Jan 26
4:39am ET
Titan Pharmaceuticals Regains Compliance with Nasdaq Listing
Jan 25
4:37pm ET
Titan Pharmaceuticals fully compliant with NASDAQ listing criteria
Jan 08
7:50pm ET
Titan Pharmaceuticals trading halted, news pending
No recent press releases are available for TTNP
TTNP Financials
Key terms
Ad Feedback
TTNP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TTNP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
